Lab
Laboratorio Clinico Corozal, INC.
Laboratorio Clinico Corozal, INC. was paid $779K by Medicaid between Jan 2018 and Dec 2024, across 41 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 17% of everything it billed.
33Billing provider infoLABORATORIO CLINICO COROZAL, INC.
COROZAL, PR 00783
COROZAL, PR 00783
33aNPI1578719050assigned 08/15/2008
33bProvider typeClinical Medical Laboratory
28Total paid$779K
24GClaims54,311
24DCodes billed41
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#166 of 777
Median peer was paid$278K
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,826 | $75K | |
| 2019 | 5,628 | $55K | |
| 2020 | 7,662 | $94K | |
| 2021 | 10,152 | $204K | |
| 2022 | 8,006 | $157K | |
| 2023 | 7,764 | $103K | |
| 2024incomplete | 7,273 | $93K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 17% | 3,048 | 2,913 | $134K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 12% | 3,936 | 3,679 | $95K |
| 84443 | Thyroid stimulating hormone (TSH) | 10% | 4,640 | 4,522 | $81K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9.6% | 9,200 | 8,608 | $75K |
| 80053 | Comprehensive metabolic panel | 7.6% | 5,417 | 5,123 | $59K |
| 80061 | Lipid panel | 7.5% | 4,171 | 4,062 | $58K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.4% | 3,453 | 1,760 | $42K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 5.0% | 763 | 729 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.2% | 667 | 634 | $33K |
| 86738 | 2.9% | 1,443 | 1,427 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.9% | 2,237 | 2,180 | $23K |
| 81001 | 2.7% | 6,376 | 6,140 | $21K |
29 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.5% | 636 | $20K |
| 86328 | 1.9% | 799 | $15K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.4% | 1,246 | $11K |
| 84439 | 1.3% | 1,091 | $10K | |
| 86701 | 1.3% | 1,052 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 809 | $7K |
| 82274 | <1% | 282 | $5K | |
| 84153 | <1% | 213 | $4K | |
| 87088 | <1% | 394 | $3K | |
| 84436 | <1% | 376 | $3K | |
| 86592 | <1% | 424 | $2K | |
| 82043 | <1% | 223 | $1K | |
| 86140 | <1% | 216 | $1K | |
| 82947 | <1% | 293 | $1K | |
| 82607 | <1% | 52 | $840.16 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 85 | $738.33 |
| 85651 | <1% | 132 | $462.24 | |
| 87177 | <1% | 90 | $451.11 | |
| 83655 | <1% | 37 | $448.46 | |
| 86803 | <1% | 12 | $184.42 | |
| 85610 | <1% | 35 | $115.83 | |
| 82270 | <1% | 28 | $105.95 | |
| 85730 | <1% | 16 | $91.56 | |
| 82950 | <1% | 17 | $88.06 | |
| 82465 | <1% | 28 | $86.21 | |
| 84478 | <1% | 15 | $69.00 | |
| 87181 | <1% | 15 | $62.61 | |
| 82565 | <1% | 13 | $39.80 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 331 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDE JESUS, MILAGROS (DIRECTOR)